Eli Lilly Raised Its Forecast to $85-$87 Billion-Is Lilly a Buy or a Bubble?

Lilly's raised 2026 forecast points to stronger demand

Eli Lilly now expects $85 billion to $87 billion in 2026 revenue, up from $82 billion to $85 billion. For a company of this size, that is a meaningful reset to the top line and a sign that demand remains stronger than management's earlier outlook.

The operating evidence backs that up. Lilly posted Q2 revenue of $23.0 billion, up 48%, with growth driven primarily by Mounjaro and Zepbound volume. That is straightforward, easy-to-verify strength: patients are staying in treatment and the sales are showing up quarter after quarter.

Competitors are pressing back, and pricing pressure is real. Still, the broader opportunity looks intact: analysts expect the U.S. obesity market to be worth more than $100 billion by the end of the decade. That does not settle the stock debate, but it does suggest the category is large enough to support continued growth for the leader.

The growth looks operational, not cosmetic

Volume is doing the heavy lifting

The key question is whether Lilly is selling more medicine or just selling it cheaper. In the first quarter, Q1 revenue increased 56% to $19.8 billion primarily driven by volume growth, even as lower realized prices on Mounjaro and Zepbound weighed on the mix. That matters because it shows demand held up even with some price pressure.

Lilly followed that with Q2 revenue of $23.0 billion, up 48%, again driven primarily by Mounjaro and Zepbound volume. When sales keep climbing after price pressure appears, it usually means patient retention and prescription continuity are still strong.

Price pressure is real, but it is not proof the story is broken

Bears have a fair point: lower realized prices mean Lilly is not operating in a friction-free market. Diabetes and obesity treatments can face rebate pressure, formulary challenges, and payer resistance. If that pressure worsens, future growth could look softer even if patient demand remains healthy.

For now, the cleaner read is that the core demand is durable and the price pressure is a watchpoint, not evidence that the growth story is fake.

Retatrutide is the next proof point

Lilly is not resting on a single franchise. The FDA approved Foundayo (orforglipron) for adults with obesity, expanding Lilly's obesity platform beyond injectables, and Lilly said three additional Phase 3 trials of retatrutide in obesity were complete, with plans to submit a Biologics License Application in the first quarter of 2027.

The most eye-catching data point was retatrutide at roughly 19% weight loss at the 4 mg dose. That result looks competitive with existing best-in-class therapy and suggests Lilly may have a next-generation obesity candidate ready to absorb demand if development and regulatory timelines hold.

Why the timing matters now

Lilly raised its forecast after posting a 48% Q2 revenue increase, and Novo Nordisk also hiked its full-year profit and sales forecast. That broader industry signal suggests the obesity market is still expanding rather than peaking.

That shifts the debate. The question is no longer just whether demand is real. It is how much of that durability and category growth is already priced into Lilly's shares. For investors, the next few quarters should provide the clearest test: if volumes stay strong, pricing pressure stabilizes, and pipeline milestones land on time, the current outlook looks more like a growth engine than a short-lived momentum trade.